NASDAQ: BLFSBiolife Solutions Inc Stock
$15.14-0.86 (-5.38%)
Updated Apr 17, 2024
BLFS Price
$15.14
Fair Value Price
-$11.27
Market Cap
$685.84M
52 Week Low
$8.92
52 Week High
$24.50
P/E
-9.96x
P/B
2.03x
P/S
4.96x
PEG
N/A
Dividend Yield
N/A
Revenue
$143.27M
Earnings
-$66.43M
Gross Margin
32.6%
Operating Margin
-44.98%
Profit Margin
-46.4%
Debt to Equity
0.22
Operating Cash Flow
-$12M
Beta
1.51
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
BLFS Overview
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BLFS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BLFS ($15.14) is overvalued by 234.34% relative to our estimate of its Fair Value price of -$11.27 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BLFS ($15.14) is not significantly undervalued (234.34%) relative to our estimate of its Fair Value price of -$11.27 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BLFS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BLFS due diligence checks available for Premium users.
Be the first to know about important BLFS news, forecast changes, insider trades & much more!
BLFS News
Valuation
BLFS fair value
Fair Value of BLFS stock based on Discounted Cash Flow (DCF)
Price
$15.14
Fair Value
-$11.27
Undervalued by
234.34%
BLFS ($15.14) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BLFS ($15.14) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BLFS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BLFS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-9.96x
Industry
49.9x
Market
41.64x
BLFS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.03x
Industry
3.49x
BLFS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BLFS's financial health
Profit margin
Revenue
$32.7M
Net Income
-$13.4M
Profit Margin
-40.9%
BLFS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BLFS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$412.7M
Liabilities
$75.1M
Debt to equity
0.22
BLFS's short-term assets ($120.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLFS's short-term assets ($120.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLFS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BLFS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.3M
Investing
$4.0M
Financing
$9.8M
BLFS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BLFS vs Medical Stocks
Biolife Solutions Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.